Form 4: AIM ImmunoTech Director Acquires Shares in Lieu of Cash Compensation
SEC Form 4 Filing
Director Nancy Bryan acquired 24,452 shares of AIM ImmunoTech stock in lieu of cash compensation under the company's Cash Conservation Plan.
Summary
- Nancy Bryan, a director at AIM ImmunoTech, acquired 24,452 shares of common stock on December 13, 2024.
- The shares were acquired at a price of $0.213 per share.
- This acquisition was made in lieu of cash compensation as part of the company's Cash Conservation Plan.
- Following the transaction, Ms. Bryan directly owns 85,559 shares of AIM ImmunoTech stock.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive as it shows a director's continued investment in the company and helps conserve cash, but it's a routine transaction.
Positives
- The acquisition demonstrates a director's continued investment in the company.
- The use of stock in lieu of cash helps the company conserve cash.
Management Comments
- The shares acquired on the Transaction Date were issued in lieu of director compensation pursuant to the issuer's Cash Conservation Plan.
Industry Context
This type of transaction is common in companies looking to conserve cash, especially in the biotech sector where funding can be volatile. It aligns with industry practices of using equity to compensate directors and employees.
Comparison to Industry Standards
- Many biotech companies use stock-based compensation to conserve cash, especially during development phases.
- This practice is similar to other companies that issue shares to directors and employees as part of their compensation packages.
- The specific amount of shares issued is dependent on the company's compensation policy and the value of the stock at the time of issuance.
Stakeholder Impact
- Shareholders may view this as a positive sign of director commitment.
- The company benefits from conserving cash by issuing shares instead of cash compensation.
Key Dates
| Date | Description |
|---|---|
| 12/13/2024 | Date of the share acquisition by Nancy Bryan. |
| 12/17/2024 | Date of signature on the Form 4 filing. |
Keywords
AIM ImmunoTech, Director, Share Acquisition, Cash Conservation Plan, Stock Compensation, Insider Trading, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.